- Molecular NameCisatracurium Besylate
- SynonymNA
- Weight929.161
- Drugbank_IDDB00565
- ACS_NO96946-42-8
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-1.33
- pkaN/A
- LogD (pH=7, predicted)-1.33
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.99
- LogSw (predicted, AB/LogsW2.0)8.35
- Sw (mg/ml) (predicted, ACD/Labs)9.4
- No.of HBond Donors0
- No.of HBond Acceptors14
- No.of Rotatable Bonds26
- TPSA126.44
- StatusFDA approved
- AdministrationIV only
- PharmacologyA neuromuscular-blocking drug. It is one of the ten isomers of atracurium. Its active metabolites contains less laudanosine (which causes hypotension, central nervous system excitement, and seizures) than that of atracurium. It is considered an intermediate-acting agent in terms of duration of action.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein bindingN/A
- Volume of distribution (VD)Steady state, 0.11 to 0.16 L/kg; increased in the elderly 17 to 37% and in patients with end-stage liver failure (21%).
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmUnknown due to rapid degradation
- Half life22~35 min
- Excretion10-15% unchanged
- Urinary ExcretionN/A
- Clerance4.6~5.7 ml/min/kg; decreases in those with renal failure and increases in patients with end-stage liver disease.
- ToxicityOverdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
- LD50 (rat)N/A
- LD50 (mouse)N/A